Transplantation

Cecilia BrownTransplantation & Cellular Therapy | February 1, 2023
New research suggests venetoclax-containing regimens with intensive treatment and may improve outcomes.
Cecilia BrownTransplantation & Cellular Therapy | November 15, 2022
Researchers had not previously studied the long-term impact of omidubicel...
Cecilia BrownTransplantation & Cellular Therapy | November 16, 2022
Researchers investigated its use in patients undergoing mismatched donor HSCT with post-transplant cyclophosphamide...
Advertisement
Cecilia BrownTransplantation & Cellular Therapy | November 15, 2022
First-line treatment with tagraxofusp led to an overall response rate of 75% in patients with blastic plasmacytoid...
Kerri FitzgeraldAcute Lymphoblastic Leukemia | November 16, 2022
Aaron Logan, MD, PhD, and Elias Jabbour, MD, discussed whether MRD negativity indicates a cure in patients with AML.
Cecilia BrownMyeloma | November 22, 2022
A triplet treatment plus autologous stem-cell transplantation was associated with longer progression...
Advertisement
Leah SherwoodTransplantation & Cellular Therapy | November 22, 2022
Nearly a third of patients with chronic graft-versus-host disease (GVHD) were able to discontinue long-term systemic therapy ...
Leah SherwoodAggressive B-Cell Lymphoma | November 22, 2022
The European Medicines Agency validated a type II variation for the extension of the indication for lisocabtagene maraleucel ...
Leah SherwoodAcute Myeloid Leukemia | November 14, 2022
Mocravimod is a synthetic, sphingosine 1-phosphate receptor modulator that has been assessed in phase I and II trials.
Leah LawrenceAcute Myeloid Leukemia | February 2, 2023
Mocravimod is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator.
Leah SherwoodAcute Lymphoblastic Leukemia | February 2, 2023
There was a global increase of 6.2% in autologous HSCT and 7.0% in allogeneic HSCT.
Leah LawrenceTransplantation & Cellular Therapy | February 2, 2023
Researchers retrospectively analyzed 580 patients with AML receiving HSCT between January 1999 and November 2020.
Leah LawrenceHodgkin Lymphoma | November 14, 2022
Long-term lymphoma survivors who underwent transplant had impaired health-related quality of life.
Ariel DeMaioAcute Lymphoblastic Leukemia | February 2, 2023
Drs. Short and Webster, discussed their differing views of the current position of transplantation in the treatment of ALL.
Sabrina AhleTransplantation & Cellular Therapy | November 14, 2022
Abatacept has been U.S. Food and Drug Administraion (FDA)-approved as acute graft-versus-host disease (aGVHD) prophylaxis for ...
Brandon MayTransplantation & Cellular Therapy | November 14, 2022
Life expectancy has improved since 1974 but remains 20.8% lower compared with the general population.
Rebecca AraujoMantle Cell Lymphoma | September 23, 2021
A study found that for people with MCL, patient demographics were associated with likelihood of receiving ASHCT.
Rebecca AraujoTransplantation & Cellular Therapy | August 23, 2021
Return to work is a marker of functional recovery in patients with cancer.
Rob DillardTransplantation & Cellular Therapy | June 30, 2021
Most guidelines recommend induction therapy followed by autologous HCT.
Rebecca AraujoMyeloma | May 24, 2021
Clinical guidelines recommend upfront AHCT for eligible patients with MM.
Advertisement
Advertisement
Editorial Board